• Pure Extracts Technologies Corp. has announced plans to expand, build fourth unit in dedicated towards research, development of psilocybin
• Announcement on its expansion plans come shortly after the Company revealed it plans to apply to Health Canada for a Dealer’s License
• Award of Dealer’s License would allow Pure Extracts to cultivate, harvest and procure controlled substances and carry out research into psychedelic compounds such as psilocybin and psilocin – paving way towards future commercialization of its product
• The Dealer’s License application has taken on increased relevance following Health Canada’s decision to revise existing regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company, recently revealed that it had begun the buildout of the fourth unit in its 10,000 square foot purpose built and British Columbia-based facility for the extraction of mushrooms in order to conduct research and development of psilocybin under a Dealer’s License (https://ibn.fm/3qqJe). The news of its expansion plans come shortly after Pure Extracts announced that the Company would be applying to Health Canada for a Dealer’s License under the Controlled Drugs and Substances Act (“CDSA”). The CDSA, which oversees the legal access to controlled substances and regulates the production, distribution, and sale of these substances in Canada, requires companies to obtain regulatory approval from Health Canada prior to carrying out activities within the sector (https://ibn.fm/fcgs3). Further to the announcement regarding the license application, Pure Extracts also seized the opportunity to state that the Company had retained a globally recognized operations, compliance, and regulatory firm to advise on its application to thereby ensure the Company’s adherence to the criteria put forth by the regulatory body. If obtained, the Dealer’s License would enable Pure Extracts to cultivate, harvest and procure controlled substances – including the likes of psychedelic mushrooms for the purpose of psilocybin extraction, conduct research into controlled substances and ultimately engage in the sale of these substances through a variety of different channels. “As a plant-based extractor bringing functional mushroom products to market in Q1 2021, we are very excited to be building-out our facility for our move into the controlled substances world of psychedelics,” commented Pure Extracts’ CEO Ben Nikolaevsky regarding the expansion plans. “It’s great to have space adjacent to our cutting-edge facility which is built to Health Canada standards and to know that this space will also have the same high standards of construction that Pure Extracts prides itself on.” The planned application has gained further relevance in light of Health Canada’s recent decision to revise the Special Access Programme (“SAP”) and related regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments (https://ibn.fm/YA6ag). Initially announced on December 11, 2020, the revision of the SAP would effectively enable the use of mushroom extracts in a range of new medical applications—including within the complex and ever-broadening mental health sector. Pure Extracts seized the occasion to announce a collaboration with Dr. Alexander MacGregor, a distinguished Professor of Biopharmaceutics and current President of the Toronto Institute of Pharmaceutical Technology (“TIPT”) ahead of the proposed regulatory changes and the outcome of the Company’s Health Canada license application. Pure Extracts and Dr. MacGregor are set to collaborate on the development and research of optimum psilocybin extraction methodologies, thus laying the groundwork to service the needs of the rapidly advancing growth and demand within the sector. Nikolaevsky elaborated on Pure Extracts’ corporate prospects within the functional mushrooms space ahead of the anticipated regulatory changes, “The Special Access Programme may prove to be the tipping point and fundamental milestone event that eventually transforms an entire segment of the medical community’s outlook towards the treatment of mental health conditions. Here at Pure Extracts, we believe in the future of the mushroom-based drug development sector and are committed to building shareholder value based on the growing number of positive indicators for future success.” For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Market for CBD-based pain relief products is growing rapidly, projected to reach $20 billion by 2024
• CNSC is a biotech company that produces fast-acting CBD products under the Xceptol brand
• Xceptol products are formulated with exclusive technology that increases absorbability, bioavailability, shelf life
• Third-party testing on Xceptol suggests 400% increase in skin penetration, 300% increase in gut absorption when compared to regular oil-based CBD

CannAssist International (OTCQB: CNSC), owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand – a line of cannabidiol (“CBD”) products that promises increased absorption, bioavailability and longer shelf life. An aging population coupled with increased chronic stress among younger people contributes to the rapidly growing market for CBD-based pain relief products—a market projected to reach $20 billion by 2024 (https://ibn.fm/eJhu9). Cannabidiol – a therapeutic component of the cannabis plant—has been studied extensively and has been shown to reduce inflammation while providing pain relief (https://ibn.fm/SsOQw). As concerns about the dangerous toxicity of mainstream pharmaceuticals like Acetaminophen continue to rise (https://ibn.fm/eVMfu), more people than ever before are turning to CBD for a gentler way to relieve pain and reduce inflammation. CiBiDinol is created using a proprietary process specifically developed to overcome numerous critical issues with oil-soluble CBD molecules. These include treatment administration, absorbability, bioavailability, and the short shelf-life of oil-based CBD products. Through the company’s proprietary process, CBD molecules are combined with penetration-enhancing cyclodextrin to cover the surface of the oil-soluble CBD molecule in a water-soluble carrier rendering it water dispersible. The resulting product has been shown to enhance absorption through the skin and gut with the overall goal of administering CBD in a way that is better aligned with the body’s natural bioactivity. Due to increased absorption, CNSC believes that its technology also offers a more potent product with greater efficacy per dose. Testing conducted via third-party services has confirmed these claims, suggesting that products created with CiBiDinol demonstrate a 400% increase in skin penetration along with a 300% increase in the rate of gut absorption when compared to regular oil-based CBD (https://ibn.fm/9S1Ys). Given the outcome of these tests, the company believes that the amount of CBD needed to achieve the targeted therapeutic effects can be reduced significantly, resulting in reduced costs for both manufacturers and consumers. Since its launch in September 2020, the Xceptol line of products includes five National Drug Codes topical pain creams utilizing ingredients registered with the FDA, capsules and tinctures. Xceptol’s CiBiDinol products are sold online through the Range Me product marketplace along with geographical distributors across established sales channels in North America.  Efforts to establish international distribution channels are underway in Central America, South America, South Africa, the EU, the UK and the Philippines. With the goal of targeting the pain-relief market, Xceptol products will be marketed through multiple social media campaigns using celebrities and former athletes associated with Freedman Sports Promotional Relations. Headquartered in San Diego, California, CannAssist was established in May 2017 with the goal of providing superior CBD products for a growing diverse market. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• 70% of those with epilepsy could live seizure-free lives if properly diagnosed, treated
• Machine-learning algorithms using EEG signals have potential to accurately predict epileptic seizures, allowing patient to take preventive measures
• NeuroCap provides cost-effective solution that is disrupting EEG market

Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics with cutting-edge technology that bridges the widening gap in access to quality care. The use of artificial intelligence (“AI”) and machine learning (“ML”) is at the forefront of improving epileptic patients’ access to neurological care.

According to the World Health Organization (“WHO”), 50 million people worldwide have epilepsy (https://ibn.fm/NUPCJ). Approximately 70% of those people could live seizure-free lives if properly diagnosed and treated. Seizures are controllable. Through a pilot program, WHO discovered that by merely training primary health-care providers to diagnose and treat epilepsy, more people would have access to the treatment they need.

However, with conventional methods the necessary diagnostic equipment is cumbersome, complicated, and expensive; it also requires a trained technician to administer the tests. A more portable, simple-to-administer test is needed to reach the majority worldwide.

In the United States alone, an estimated 2.3 million adults and more than 450,000 children and adolescents live with epilepsy, with an estimated 150,000 people diagnosed each year (https://ibn.fm/bbcbW). Tragically, access to neurological care is decreasing as the need grows. In 2017, 20 states were considered neurology deserts, meaning they had less than 10 neurologists per 10,000 patients (https://ibn.fm/gnbtU).

A 2019 Advisory Board brief, titled “Navigating the Neurologist Shortage,” reported that the situation was not improving (https://ibn.fm/rP1Nc). “Providers across the country currently struggle to hire neurologists—and the problem shows no sign of abating. Estimates show that demand for neurologists in 2025 will exceed supply by 19%,” the report observed. This makes the wait for essential diagnosis and treatment long — and sometimes dangerous.

The solution may well be BRSF’s neuro-tech ecosystem. This approach consists of the disposable NeuroCap(TM) and a portable wireless NeuroEEG(TM) amplifier. These products provide rural hospitals with easy access to EEG tests.

Machine learning has improved EEG analysis and solved several challenges. Brain Scientific is working on incorporating AI and machine learning processes into the analysis, which will be able to free neurologists from the manual, tedious, and time-consuming portions of their jobs, thereby allowing them to help more patients.

According “Machine Learning for Predicting Epileptic Seizures Using EEG Signals,” which was published in February 2020, when an epileptic seizure is predicted in advance it is possible to take preventative interventions (https://ibn.fm/GXlG2). Machine learning algorithms using EEG signals have the potential to accurately predict epileptic seizures. This state-of-the-art hope for epilepsy still has problems, “cost-effective and efficient hardware implementation remains the bottleneck.”

Brain Scientific is working to disrupt the expensive EEG market. The NeuroCap and NeuroEEG are both approved by the FDA and provide economic and disposable substitutes. Trained technicians are not required to administer the tests, and a neurologist does not have to be on-site to run the analysis. A telemedicine physician can read the results in real time, eliminating long waits, high costs and the risks of exposure to communicable diseases such as COVID.

Brain Scientific is working to make neurological care accessible for all who need it.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• COVID-19 cases projected to continue to increase in coming weeks, months
• UMEBSNI is trusted supplier of FDA-approved COVID-19 rapid antigen test kits
• United Medical offers additional comprehensive programs for COVID-19 testing

Even as COVID-19 vaccines are finally being approved and distributed, the latest forecast from the Centers for Disease Control and Prevention (“CDC”) predicts that an up to 2 million new COVID-19 cases will likely be reported in the week ending Jan. 16, 2021 (https://ibn.fm/0cNyq). The global pandemic is not yet over, and United Medical Equipment Business Solutions Network Inc. (“UMEBSNI”) continues to move quickly to address the unique testing needs created by the ongoing virus.

As part of its efforts to provide essential services during the epidemic, UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits (https://ibn.fm/hZ43R). The COVID-19 IgG/IgM Rapid Test Cassette offered by United Medical detects coronavirus antibodies that appear in the bloodstream of individuals infected with the virus within 10 minutes. The test can also indicate whether a person has protection against the coronavirus.

Other features of the test include the following:

• FDA Emergency Use Authorization (“EUA”)
• Small sample sizes; works with whole blood, plasma and serum samples
• Shelf life of up to 24 months from date of manufacture
• Stored at room temperature or refrigerated (2 to 30°C)
• Available in quantities of 25

The kits are for medical professional use only and are approved for use in CLIA moderate- or high-complexity settings. In addition, verification of use case prior to shipping is mandatory.

The IgG/IgM rapid test kits are only the beginning of UMEBSNI’s commitment to offering comprehensive programs for COVID-19 testing. Other services provided by the company include pre-shift temperature checks, medical-grade face masks, hand-sanitizer stations, medical-grade nitrile gloves and face shields.

Finally, the company also offers a unique mobile solution. UMEBSNI mobile testing specialists and experienced medical staff members are available to provide onsite COVID-19 Rapid Testing and solutions to implement employee safety. Mobile units and medical staff are on call and are capable of nationwide deployment for extended periods of time.

United Medical Equipment Business Solutions Network is a provider of reliable resources and solutions to fit the ever-changing needs of an aging population that includes seniors and veterans, as well as those impacted by the COVID-19 pandemic. Uniquely poised to offer health care across the continuum of care, United Medical Equipment has solutions that help providers work more proficiently, health-care systems work smarter and patients live healthier lives.

The company aims to provide the information, technology and proper equipment needed to maintain safety and health among seniors, veterans, health-care workers and other patients.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• U.S. taking actionable steps toward acceptance of psilocybin
• States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority
• More psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels

Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of psychedelic products. The company’s subsidiary Serenity Life Sciences is focused on the research and development of psilocybin-based medications. Psilocybin, referred to by the media as magic mushrooms, has had its share of bad press. The stigma of this substance has halted R&D in America in the past, but that is beginning to change. Under the Controlled Substances Act, psilocybin is included with heroin and LSD as a Schedule I drug. According to the National Drug Intelligence Center, psilocybin serves no legitimate medical purpose in the United States (https://ibn.fm/Z23k3). This view has come under criticism as recent studies surrounding the substance show otherwise. The public’s opinion, state guidelines and pharmaceutical development of psychedelic products are moving towards growing acceptance and legalization. Oregon became the first state to legalize the use of psilocybin for therapeutic use when voters passed Measure 109 on Nov. 3, 2020 (https://ibn.fm/TKCuc), the latest in several steps the country hs been taking toward psilocybin acceptance. In 2005 the Court of Appeals in New Mexico overturned a felony drug trafficking conviction by citing that growing hallucinogenic mushrooms isn’t prohibited under the drug trafficking law’s definition of “manufacture” (https://ibn.fm/yRUSw), marking one of the first indications of what would be a slow-changing tide. Fifteen years later, New Jersey amended a marijuana decriminalization bill to include a lesser punishment for possession of psilocybin from a third-degree felony to a disorderly persons offense (https://ibn.fm/dmb3p). In addition, where states are not decriminalizing psilocybin, individual cities are. Denver was the first U.S. city to decriminalize psilocybin mushrooms. Ordinance 301 was passed with a 50.56% majority in May 2019 (https://ibn.fm/pX7ii). This ordinance keeps the city from prosecuting or arresting adults in possession of or even growing the mushrooms. Other cities across the country have followed suit. Oakland, California, passed a law the following month banning law enforcement from investigating and prosecuting individuals using or possessing drugs sourced from plants, cacti and mushrooms that contain psilocybin (https://ibn.fm/nEBhR). The third city was also in California. Santa Cruz’s City Council voted unanimously in January 2020 to make the investigation and arrest for adult possession, use or cultivation a low-priority infraction (https://ibn.fm/YlVE9). In another unanimous vote in September 2020, Ann Arbor, Michigan’s City Council voted in favor of declaring the investigating and arrest of anyone for planting, cultivating, purchasing, transporting, distributing, engaging in practices with or possessing psilocybin the city’s lowest law enforcement priority (https://ibn.fm/pooRa). All four cities citied indigenous cultural reasons as well as research around the use of psychedelics in the treatment of mental health and as a viable option combating the opioid crisis. More movement is being seen in the decriminalization and push for research across the United States.

• Alexandria Ocasio-Cortez filed legislation for researchers to more easily study the benefits of psychedelic drugs (https://ibn.fm/vDEHF)
• Jeff Shipply filled a bill in the name of personal freedom to decriminalize psilocybin in Iowa
• Initiative 81, voted on by D.C. residents and awaiting review by Congress, makes the possession and use of certain psychedelic plants low priority for the police (https://ibn.fm/yT730)

Criminalization and the stigmas attached have made it difficult for researchers to explore the medical benefits of psilocybin and other psychedelics. As more states accept the cultural and medical benefits of these substances, more research can be done, which could ultimately lead to increased health and well-being of Americans who are facing a mental health crisis on epic levels. With more than 17 million people in the Unted States experiencing at least one major depressive episode (https://ibn.fm/0Wxky), it is past time for new treatment alternatives. Cybin is at the forefront of companies conducting clinical trials for potential new treatment options and is developing innovative approaches to bring new psychedelic-based therapies to patients in need. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• UUUU to receive minimum of 2,500 tons of natural monazite ore, one of highest-grade REE minerals in world
• Company to produce raw materials needed for clean energy, advanced technologies while also creating green jobs in economically underserved area
• Energy Fuels will be first U.S. company in years to produce marketable mixed REE concentrate on commercial scale

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a diversified uranium miner, has finalized a three-year agreement with the Chemours Company (NYSE: CC) to obtain natural monazite ore, one of the highest-grade rare earth element (“REE”) minerals in the world (https://ibn.fm/Rp4YN). The agreement calls for Energy Fuels to receive a minimum of 2,500 tons per year and represents a significant step in UUUU’s commitment to be a leader in re-establishing a fully integrated U.S. REE supply chain.

“With our announcement . . .  Southeast Utah is fast becoming America’s clean energy and critical minerals hub,” Energy Fuels president and CEO Mark S. Chalmers stated. “Our goal is to domestically produce the raw materials needed for clean energy and advanced technologies, while creating green jobs in an economically challenged part of the country.

“Currently, the U.S. imports nearly all of our rare earth, uranium and vanadium requirements, despite having ample supplies here in the U.S.,” Chalmers continued. “Importantly, in the United States we are highly regulated and operate to the highest standards, which means we produce these minerals more responsibly than many of the countries from which we currently import. Our agreement with Chemours may be the beginning of a real success story, not only for Energy Fuels, but also for local communities, Native Americans, conservation groups, the State of Utah, and the U.S. as a whole.”

Based on the announcement, Energy Fuels intends to start process the monazite it receives from Chemours beginning the first quarter of 2021. The process will take place at UUUU’s wholly owned White Mesa Mill, which is located in Utah. The company will recover the uranium that results from that process and produce a marketable mixed REE carbonate, an essential step toward re-establishing a fully independent U.S. REE supply chain.

Once Energy Fuels successfully begins this process, UUUU will be the first company in the United States in years to produce a marketable mixed REE concentrate ready for separation on a commercial scale. Based on its estimates, UUUU plans to be able to provide almost 10% of total current U.S. REE demand. REEs are used in a wide variety of clean energy and advanced technologies, including wind turbines, electric vehicles, cell phones, computers, flat-panel displays, advanced optics, catalysts, medicine and national defense applications.

Energy Fuels’ mixed REE carbonate production from monazite ore should use only a  small amount of its White Mesa Mill’s ore-production capacity and produce almost no waste. Initially, UUUU plans on obtaining the 2,500 tons of monazite sands from Chemours, as outlined in the contract, but the company will work to increase monazite ore supply, hopefully reaching approximately 15,000 tons of monazite ore per year. The White Mesa Mill is licensed and designed to process 2,000 tons of ore daily, or 720,000 tons of ore per year, so the anticipated production of monazite sands represents an estimated 2% of its throughput capacity. If successful at reaching those numbers, Energy Fuels projects its White Mesa Mill will be able to produce approximately 50% of U.S. REE demand in a mixed REE carbonate.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Demand for food increasing as world population swells; pesticides paramount to maintain supply
• Countries banning pesticides deemed hazardous, but alternatives are lacking
• MustGrow is solution provider for global food supply with its natural biological crop protection for high-value crops

As the world population is increasing at an accelerated pace, a stable food supply is becoming critical to ensure food availability across the world. MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is playing a key role in providing biotechnology that secures both steady and high-quality crop supply.

To ensure a consistent flow of produce, crops need protection. For that, producers have been using various synthetic pesticides, which have become irreplaceable in creating a stable and abundant food supply for the global population. Indispensable for controlling weeds, pests and plant pathogens that threaten crops, synthetic pesticides contribute to higher yields and improved quality.

Still, not all of pesticides are created equal; some have even been deemed hazardous by the World Health Organization (“WHO”). Some pesticides on that hazardous list are still being used around the world, including in the United States. A recent article cites that around 150 agricultural pesticides considered hazardous to human health by WHO were used in the United States within the last few years (https://ibn.fm/wVmJt).

Although using potentially risky compounds has been an accepted part of the global food industry, the pressure to move away from that is growing. Both industry and governments are increasingly recognizing the importance of natural products to secure a quality food supply for the world while keeping health and safety in mind.

Although some jurisdictions are more advanced in scrutinizing the use of chemical pesticides in human consumption at present — resulting in some of those substances being banned — with globally integrated food supply chains, the world will likely see the convergence of these regulations on the international scale. As this happens, natural alternatives to chemical pesticides will become paramount to ensure a steady stream of crops while also adhering to strict health and safety standards (https://ibn.fm/3kU0S).

As bans on certain chemical pesticides continue to spread, natural alternatives are needed to fill this gap and secure the global food supply. To transition effectively away from chemical pesticides, new “biological” products need to have not only a safer and more eco-conscious profile but comparable efficacy and pricing as well. This is where MustGrow steps in.

As an agriculture biotech company committed to creating natural biological crop protection for high-value crops, MustGrow positions itself as a critical part of the food ecosystem of the future. The company has developed EPA-approved biotechnology that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases, offering a natural solution as an increasing number of markets seek natural alternatives for chemical pesticides.

Focused on developing breakthroughs in agriculture to enable farmers to use natural, safe and efficient products, MustGrow is a part of the solution to the global food supply problem with its unique, natural and organic product. As the market gap widens, MustGrow’s solution is showing comparable efficacy, consistency and potentially price compared to traditional synthetic chemicals, opening a global opportunity for the pioneering company to leverage the rising demand and help maintain both stable and high-quality food supply.

For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Wisp Resort has already covered 9,311 room nights and counting with InsuraGuest Hospitality Liability coverage
• The company’s Hospitality Liability Policy helps reduce properties’ risk and claim ratio, which could potentially lower the premiums for General Liability coverages
• InsuraGuest is disrupting the current insurance market by offering digital insurance solutions across multiple sectors – not just hospitality

Innovative insurtech provider InsuraGuest Technologies (TSX.V: ISGI), through the wholly-owned United States subsidiary, InsuraGuest Risk Purchasing Group, Inc., has announced that its annual contract with Wisp Resorts over the Hospitality Liability Coverage has been renewed (https://ibn.fm/7zEtW). Following the renewal, Wisp Resort, the only four-season ski, golf, and recreational destination resort in the mountains of Western Maryland, will continue to provide InsuraGuest Hospitality Liability Policy coverage to its 168-room resort. To date, Wisp has covered 9,311 room nights and counting. By harnessing the power of technology, InsuraGuest has changed the way that insurance is delivered to hotels and vacation rentals. The company’s Hospitality Liability coverage was designed to help the property transfer certain risks away from their General Liability insurance by adding a layer of protection for the property should a guest experience a mishap or accident. This way, the policy helps pay for accidental in-room property damage, lost or stolen goods, medical payments, and accidental death and dismemberment. These often have limitations or high deductibles when exposed to the company’s General Liability insurance coverages. Adversely, some of the claims turned in to General Liability are so small yet create a big impact. The more claims that you have, the higher risk you are. If you are considered a high-risk company, your premiums are higher. With InsuraGuest, hotels and vacation rentals now have the ability to help manage their insurance premiums by transferring certain risks onto the Hospitality Liability policies InsuraGuest provides. Hotel operators can even generate revenue using InsuraGuest. Coverage is activated upon a guest checking into an InsuraGuest covered property. The charge is placed on the guest’s folio, or it is bundled into the resort/amenity/urban fees. The hotel keeps 10% of this charge for their own revenue. The contract with Wisp Resorts is one of several partnerships InsuraGuest has made lately to further cement its leading position on the fast-growing insurtech market. With technology touching almost every industry worldwide, the insurance industry has been no exception. Valued at $5.48 billion in 2019, the global insurtech sector is expected to reach $10.14 billion by 2025, with a CAGR of 10.8% during the forecast period of 2019-2025 (https://ibn.fm/udChj). This growth offers multiple opportunities to InsuraGuest, a company committed to harnessing the power of technology to reinvent the insurance industry. With a proprietary software platform that delivers digital insurance to multiple sectors across various industries, the company aims to revolutionize the way insurance is delivered based on the idea that insurance should be bought and not sold. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Autonomous Security Robot (ASR) developer Knightscope has deployed its high-tech sentries at institutions including hospitals, universities, Fortune 1000 companies and even on behalf of NBA team the Sacramento Kings
• Knightscope counts law enforcement personnel and private security industry directors among its Reg A+ investors, who now number more than 17,000 people
• The company recently launched a new app through which its friends can help Knightscope identify ideal locations for ASR security products
• Market analysts predict the global ASR market will grow at a CAGR of 7.93 percent through 2025 to $3.59 billion

Autonomous security robot (“ASR”) developer Knightscope is helping to revolutionize the operations of protective patrols used by private industry as well as the police forces employed by governmental institutions. The company’s indoor and outdoor-mobile ASR sentries have been contracted to help safeguard hospitals, university campuses, an NBA team and numerous Fortune 1000 companies. As evidence of the robots’ effectiveness and success, Knightscope’s investors number more than 17,000 now, among whom are law enforcement personnel and private security industry managers. A Public Safety App just launched by Knightscope in December on both the App Store and Google Play aims to help the company expand its clientele by inviting app users to report any location where they think an Autonomous Security Robot (“ASR”) will contribute to public safety. “Record a video, enter some basic information about the location and submit. Knightscope will follow up on each submission directly and present a solution to the appropriate officials,” a news release about the launch states (https://ibn.fm/0FM7A). The indoor and outdoor robots operate with artificial intelligence-enhanced features such as 360-degree eye-level HD streaming video and speakers for live or recorded communication, data collection and recording, obstacle avoidance, facial recognition, license plate identification, thermal fluctuation detection and broadcast signal reception. Mordor Intelligence analysts predict the global ASR market will grow at a CAGR of 7.93 percent through 2025, from $2.27 billion last year to $3.59 billion (https://ibn.fm/U6aNw), adding that “developments, like K5 by Knightscope, Inc., are indicating a potential future scope for security robots. Earlier, these robots had insufficient capabilities; however, with advances in sensor technology and automation capabilities, these robots have been developed to be useful in working applications.” For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Gold hit all-time high as investors flock to protect wealth on the fear of inflation, economic turmoil, currency fluctuations
• To leverage strong momentum of gold, investors may benefit from junior mining stocks
• GoldHaven appears to be well positioned to capitalize on rising attractiveness of gold market

Historically, gold played the role of a safe haven asset during economic decline or increased volatility due to heightened uncertainty. The pandemic has been no different as the precious metal hit its all-time high in early August, surpassing $2,075 per ounce. With the expectation that the price of the precious metal will stay strong in 2021, GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) looks to be well positioned in the space. As a junior mining company focused on identifying and capitalizing on precious metal projects in mineral-rich districts within stable political jurisdictions, GOH may well be able to leverage the robust momentum of the gold market.

In the latest gold price surge, another driving force emerged — government spending at unprecedented levels. To fight the damaging effects of a looming recession, central banks inject cash into the financial system, a mechanism called monetary easing, while governments embark on a spending spree. Since the onset of the pandemic, the government has injected trillions of dollars, leading to public debt hitting an all-time high in the post-World War II years (https://ibn.fm/6pok8).

These factors traditionally lead to inflation, which in turn pushes up the price of gold. Also, monetary easing lowers investor confidence in the currency’s strength, which then increases the demand for gold as a safe haven. The U.S. Dollar Index tracks the value of the US dollar against a basket of major currencies such as the euro, Japanese yen, pound sterling, Canadian dollar, Swedish krona and Swiss franc. After a spike around the onset of the pandemic, the U.S. Dollar Index shows that the currency has been declining steadily for most of 2020 (https://ibn.fm/i3RFB), making gold even more attractive as an investment alternative.

Investors have various options in gold investing, including buying physical gold or stocks of gold mining companies. Physical gold includes gold bullion, coins and jewelry, for which investors usually need to pay for storage and insurance. Alternatively, they can invest in gold mining companies. As a junior mining company, GoldHaven is poised to benefit from the favorable market environment for gold. According to a recent article published by “Forbes,” investing in junior gold miners may be more attractive during the volatile bull market than larger gold miners (https://ibn.fm/rJX3J).

A gold mining company is worth the value of its gold reserves. Larger companies tend to mine a lot of gold, effectively depleting their reserves every year. To replenish those resources, larger mines can either do explorative work to find new deposits or buy another company with a gold ore stock, which is less risky. As gold price surges, junior miners become more likely to get taken over by larger miners, potentially making their stock prices rally. Also, new gold deposits could make a large difference to a junior miner’s value, while for bigger companies, the impact is usually much smaller. These factors all contribute to the attractiveness of junior miners in times of a strong gold market.

As a Canadian junior exploration company led by a seasoned executive team, GoldHaven is poised to thrive in today’s gold-market environment. With mining assets located in stable political jurisdictions such as the Maricunga Gold Belt of Northern Chile, GoldHaven Resources believes it leverages the right people, the right product, and the right time to capitalize on this favorable environment.

For more information, visit the company’s website at www.GoldHavenResources.com.

NOTE TO INVESTORS: The latest news and updates relating to GHVNF are available in the company’s newsroom at http://ibn.fm/GHVNF